Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of micrornas 199a-5p and 20a induction

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 661-669

  Kang, Seul Gi ^a,b   Lee, Woo Hyung ^a,b   Lee, Young Hun ^c   Lee, Yong Sup ^c   Kim, Sang Geon ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 6,8 BIS(METHYLTHIO)PYRROLO[1,2 ALPHA]PYRAZINE; 7 METHYL 6,8 BIS(METHYLSULFINYL)PYRROLO[1,2 ALPHA]PYRAZINE; 7 METHYL 6,8 BIS(METHYLTHIO)PYRROLO[1,2 ALPHA]PYRAZINE; 7 METHYL 8 (METHYLSULFINYL) 6 (METHYLTHIO)PYRROLO[1,2 ALPHA]PYRAZINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COBALT CHLORIDE; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; MICRORNA; OLTIPRAZ; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CATABOLITE REPRESSION; CELL MIGRATION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH; UBIQUITINATION;

EID: 84863241726     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr320     Document Type: Article

References (43)

1. Brahimi-Horn,M.C. et al. (2007) Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem. Pharmacol., 73, 450-457.
2. Hsu,P.P. et al. (2008) Cancer cell metabolism: Warburg and beyond. Cell, 134, 703-707.
3. Ke,Q. et al. (2006) Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol., 70, 1469-1480.
4. Belozerov,V.E. et al. (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs, 16, 901-909.
5. Folkman,J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 6, 273-286.
6. Semenza,G.L. (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29, 625-634.
7. Brown,L.M. et al. (2006) Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol. Pharmacol., 69, 411-418.
8. Yeo,E.J. et al. (2003) YC-1: a potential anticancer drug targeting hypoxiainducible factor 1 J. Natl. Cancer Inst., 95, 516-525.
9. Powis,G. et al. (2004) Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther., 3, 647-654.
10. Bolton,M.G. et al. (1993) Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res., 53, 3499-3504.
11. Shen,X. et al. (1999) Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl Cancer Inst., 91, 347-354.
12. Rao,C.V. et al. (1993) Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res., 53, 2502-2506.
13. Ruggeri,B.A. et al. (2002) The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin. Cancer Res., 8, 267-274.
14. 2-scavenging effect. Mol. Cancer Ther., 8, 2791-2802.
15. Brooks,S.C. III et al. (2009) Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol. Ther., 124, 31-43.
16. Wattenberg,L.W. et al. (1986) Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis, 7, 1379-1381.
17. O'Dwyer,P.J. et al. (1997) Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. Clin. Cancer Res., 3, 783-791.
18. Bieder,A. et al. (1983) Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittelforschung, 33, 1289-1297.
19. Kim,S.G. et al. (2010) Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1. Clin. Pharmacol. Ther., 88, 360-368.
20. Ko,M.S. et al. (2006) Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction. Drug Metab. Dispos., 34, 1353-1360.
21. Kwon,Y.N. et al. (2010) Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinasedependent cellular antioxidant effect and mitochondrial protection. Drug Metab. Dispos., 37, 1187-1197.
22. Yao,H. et al. (2008) Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int. J. Cancer, 123, 1255-1261.
23. Zhang,Q. et al. (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther., 4, 1465-1474.
24. Cho,M.K. et al. (2007) Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor. Mol. Cell Biol., 27, 6195-6208.
25. Ogata,A. et al. (2010) Biaryl modification of the 5'-terminus of one strand of a microRNA duplex induces strand specificity. Bioorg. Med. Chem. Lett., 20, 7299-7302.
26. Zelzer,E. et al. (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J., 17, 5085-5094.
27. Treins,C. et al. (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem., 277, 27975-27981.
28. Gothié,E. et al. (2000) Identification of alternative spliced variants of human hypoxia-inducible factor-1α. J. Biol. Chem., 275, 6922-6927.
29. 2 tension. Proc. Natl Acad. Sci. USA, 92, 5510-5514.
30. Clapper,M.L. (1998) Chemopreventive activity of oltipraz. Pharmacol. Ther., 78, 17-27.
31. Velayutham,M. et al. (2005a) Cancer chemopreventive oltipraz generates superoxide anion radical. Arch. Biochem. Biophys., 435, 83-88.
32. Velayutham,M. et al. (2005b) Glutathione-mediated formation of oxygen free radicals by the major metabolite of oltipraz. Chem. Res. Toxicol., 18, 970-975.
33. Velayutham,M. et al. (2007) Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention. Free Radic. Biol. Med., 43, 1076-1085.
34. Tacchini,L. et al. (2004) Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis, 25, 2089-2100.
35. Liu,Y.N. et al. (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene, 26, 3941-3951.
36. Laughner,E. et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol., 21, 3995-4004.
37. Ambros,V. (2004) The functions of animal microRNAs. Nature, 431, 350-355.
38. Brennecke,J. et al. (2005) Principles of microRNA-target recognition. PLoS. Biol., 3, e85.
39. Taguchi,A. et al. (2008) Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res., 68, 5540-5545.
40. Cha,S.T. et al. (2010) MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res., 70, 2675-2685.
41. Yeligar,S. et al. (2009) Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxiainducible factor-1alpha and microRNA-199. J. Immunol., 183, 5232-5243.
42. Li,Y. et al. (2010) Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res., 27, 1027-1041.
43. Bae,S.K. et al. (2005) Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos., 26, 99-115.